Evonik baut Produktionskapazitäten für lipidbasierte Wirkstoffe in Vancouver aus

LipidnanopartikelPositive

AI Analysis

Summary

Evonik is expanding lipid-based drug manufacturing capacity in Vancouver with a new GMP facility, investing over 150 million Canadian dollars with support from a Canadian government strategic fund to meet growing demand for lipid nanoparticle development and clinical drug manufacturing.

Importance:5/10

Sentiment:

0.60

manufacturingcapacity expansionlipid nanoparticlesGMP facilitygovernment fundingCanada

Read the original article

Published by PR Newswire Biotech on August 28, 2026 7:00 AM

Read Original